The effects of neutrophil cathepsin G on the glycoprotein (GP) Ib-fX complex of washed platelets were examined. Cathepsin G resulted in a concentration-and time-dependent decrease in the platelet surface GPL-IX complex, as determined by flow cytometry, binding of exogenous von Willebrand factor (vWF) in the presence of ristocetin, and ristocetin-induced platelet agglutination. Cathepsin G resulted in proteolysis of the vWF binding site on GPlba (defined by monoclonal antibody [MoAbl 6D1). as determined by increased supernatant glycocalicin fragment (a proteolytic product of GPlba); decreased total platelet content of GPlb;
Iz, and prior fixation of platelets. Experiments with Serratia protease-treated and Bernard-Soulier platelets showed that neither platelet surface GPlb nor cathepsin G-induced proteolysis of GPlb were required for the cathepsin G-induced redistribution of the remnant of the GPlb-IX complex or the cathepsin G-induced increase in platelet surface P-selectin. In summary, neutrophil cathepsin G modulates the platelet surface expression of the GPb-IX complex both by proteolysis of the vWF binding site on GPlba and by a cytoskeletalmediated redistribution of the remainder of the complex. Prior studies show that, although thrombospondin 1, antiserine proteases, and plasma are all inhibitors of cathepsin G, the effects of cathepsin G on platelets, including an increase in surface GPllb-llla, occur during close contact between neutrophils and platelets in a protective microenvironment leg. thrombosis and local inflammation). Taken together, the data suggest that, in a protective microenvironment, neutrophils play a role in transforming platelets from a state favoring adhesion t o damaged vessel walls (mediated by vWF binding to the GPL-IX complex) t o a state favoring platelet-to-platelet aggregation (mediated by fibrinogen binding to the GPllb-llla complex) and platelet-toleukocyte adhesion (mediated by P-selectinl. spondin 1 ,22 and antiserine pro tease^.^' However, recent studhave provided evidence that the cathepsin G-mediated effects of neutrophils on platelets can occur during close contact between neutrophils and platelets in a protective microenvironment (eg, thrombosis and local inflammation).
The thrombin-induced decrease in the platelet surface expression of GPIb is not the result of p r o t e~l y s i s '~.~~ or a conformational change,'' but is the result of a cytoskeletalmediated translocation of the entire GPIb-IX complex to the membranes of the open surface canalicular system.ln In contrast, a number of proteases (eg, calcium-dependent protease,2h Serratia marcescens p r o t e a~e ,~~.~* p l a~m i n ,~~-~' and neutrophil ela~tase"~'~) decrease the platelet surface expression of GPIb by proteolysis of an a chain fragment that contains the vWF binding site.
In this study, we examined the mechanism of the cathepsin G-induced decrease in the platelet surface expression of the GPIb-IX complex. We determined that cathepsin G modulates the platelet surface expression of the GPIb-IX complex both by proteolysis of the v W F binding site on GPIba and by a cytoskeletal-mediated redistribution of the remainder of the complex.
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MATERIALS AND METHODS

Murine Monoclonal Antibodies (MoAbs)
GPZb-IX-specific MoAbs. MoAbs 6D1 (provided by Dr BW S. Coller, SUNY, Stony Brook, NY) and AK2 (provided by Dr Michael C. Bemdt, Baker Medical Research Institute, Melbourne, Australia) are directed against the vWF binding site on the amino terminal domain of platelet membrane GPIba.34-3h TM60 (provided by Dr Naomasa Yamamoto, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) is directed against the thrombin binding site on the amino terminal domain of G p I b~r .~~. '~ WM23 and AK3 (provided by Dr Berndt) are directed against the macroglycopeptide portion of G P n~c t . '~,~ FMC25 (provided by Dr Bemdt) is directed against platelet membrane GPIX.41 AK1 (provided by Dr Berndt) is directed against the GPIb-IX AKI only binds to the intact GPIb-IX complex, not to uncomplexed GPIb or GPIX." P-selectin-spec$c MoAbs. MoAb S12 (provided by Dr Rodger P. McEver, University of Oklahoma, Oklahoma City) is directed against P-sele~tin."~,~ P-selectin, also referred to as GMP-140,43 PADGEM protein," and CD62,"6 is a component of the (x granule membrane of resting platelets that is only expressed on the platelet surface membrane after platelet degranulation and se~retion.'~.~'
Other MoAbs. 6F1 (provided by Dr Coller) is directed against the platelet membrane GPIa-IIa complex. 4 
Flow Cytometric Analysis of Platelet Surface GPs
The method has been previously de~cribed.~'.~' The protocol was approved by the Committee for the Protection of Human Subjects in Research at the University of Massachusetts Medical Center. Peripheral blood was drawn from healthy adult volunteers who had not ingested aspirin or other antiplatelet drugs during the previous 10 days. The first 2 mL of blood drawn was discarded and then blood was drawn into a sodium citrate Vacutainer (Becton Dickinson, Rutherford, NJ), which does not result in platelet activation?' After addition to platelet-rich plasma of citrate albumin wash buffer (128 mmoW NaCl, 4.3 mmol/L NaHzPO,.HZO, 7.5 mmol/L Na2HPO4, 4.8 mmol/L sodium citrate, 2.4 mmol/L citric acid, 0.35% bovine serum albumin, 11 mmoVL glucose), pH 6.5, with 50 ng/ mL prostaglandin (PG) El, washed platelets were prepared by centrifugation as previously described." The concentration of washed platelets was adjusted to 15O,OOO/pL in modified Tyrode's buffer (137 mmom NaCI, 2.8 mmoVL KCl, 1 mmol/L MgC12, 12 mmoU L NaHCO,, 0.4 mmol/L Na2HP04, 0.35% bovine serum albumin, 10 mmoVL HEPES, 5.5 mmol/L glucose), pH 7.4. The washed platelets (150,00O/pL) in modified Tyrode's buffer, pH 7.4, were incubated at 22°C for 20 minutes with various concentrations of purified human neutrophil cathepsin G (Calbiochem, La Jolla, CA), 1 U/mL purified human a-thrombin (provided by Dr John W. Fenton 11, New York Department of Health, Albany, NY), or control buffer. The samples were then fixed in 1 % formaldehyde for 30 minutes at 22°C. In time course experiments, the pIatelets were incubated at 22°C with 10 pg/mL cathepsin G for various time points up to 20 minutes, and aliquots were then fixed immediately with 1% formaldehyde as above. After fixation, all samples were diluted IO-fold in modified Tyrode's buffer, pH 7.4. Samples were then incubated (22°C for 20 minutes) with saturating concentrations of FITC-conjugated Y2/51 (GPIIIa-specific) and a biotinylated MoAb (6D1, TM60, WM23, FMC25, AKl, or S12), followed by incubation (22°C for 20 minutes) with 30 pg/mL PE-streptavidin (Jackson ImmunoResearch, West Grove, PA). Samples were then diluted 10-fold in modified In some experiments, before the addition of cathepsin G, the platelets were incubated at 22°C with or without (1) 10 pmoW PG& (Sigma, St Louis, MO) (an inhibitor of platelet activation) for 30 minutes, (2) 6 p m o m cytochalasin B (Sigma) (an inhibitor of actin p~lymerization~~) for 15 minutes, or (3) 2.5 pg/mL Serratia mrcescens metalloprotease (provided by Dr G.A. Jamieson, American Red Cross, Rockville, MD) for 30 minutes. The degree of proteolysis of platelet surface GPIb by Serratia protease was assessed by flow cytometry with MoAb 6D1, as previously described?'
In other experiments, washed platelets from normal donors were compared with washed platelets from a patient with Bernard-Soulier syndrome (see below).
In some experiments, washed platelets were fixed with I % formaldehyde and diluted in modified Tyrode's buffer, pH 7.4, before incubation with or without cathepsin G.
Flow Cytometric Analysis of Total Platelet GPIb-IX
The total platelet content of GPIb-IX was determined by flow cytometric analysis of permeabilized platelets, as previously de~cribed.~' Washed platelets (final concentration, 75,000/pL) were incubated at 22°C for 20 minutes with either 10 pg/mL cathepsin G, 1 U/mL thrombin, or no agonist. After fixation with 1% formaldehyde and a IO-fold dilution in modified Tyrode's buffer, pH 7.4, the platelets were incubated at 22°C for 20 minutes with an FITCconjugated MoAb (6D1, FMC25, or AK1; in ?-fold excess of the saturating concentration for platelet surface GPIb-IX) and 0.1% Triton X-IO0 (Sigma) in modified Tyrode's buffer, pH 7.4. After a further IO-fold dilution, platelet fluorescence was analyzed by flow cytometry. Nonpermeabilized controls were prepared identically, except that Triton X-100 was omitted.
Ristocetin-Induced Binding of vWF to Platelets
The ristocetin-induced binding of vWF to platelets was determined by a slight modification of a previously described method.53 Washed platelets were incubated with 10 pg/mL cathepsin G or control buffer. At various time points up to 20 minutes, aliquots vere fixed with 1% formaldehyde for 30 minutes at 22"C, diluted 40-fold with modified Tyrode's buffer, pH 7.4, and incubated (22°C for 15 minutes) with pooled platelet-poor plasma from normal donors (as a source of vWF) and ristocetin (BioData, Horsham, PA; final concentration, 1.4 mg/mL). The mixture was then incubated (22°C for 15 minutes) with 28 pg/mL of either polyclonal FITC-conjugated anti-vWF goat IgG antibody (Atlantic Antibodies, Stillwater, MN) or FTTC-conjugated nonspecific goat IgG (Atlantic Antibodies), and diluted 16-fold in modified Tyrode's buffer, pH 7.4. The samples were then incubated (22°C for 15 minutes) with a subsaturating concentration of PE-conjugated MoAb 7E3. After identification of platelets by gating on both PE positivity and their characteristic light scatter, binding of FITC-conjugated anti-vWF antibody was determined by flow cytometry. The fluorescence of the sample incu-bated with the nonspecific goat IgG was subtracted from the fluorescence of the sample incubated with the anti-vWF antibody.
Measurement of Platelet F-Actin Content by Flow Cytometry
FITC-conjugated phalloidin (Molecular Probes), which binds directly and specifically to polymerized (F) was used in a flow cytometric assay to detect platelet F-actin content. Platelets were washed, incubated with cathepsin G, and fixed, as described above. The platelets were diluted to a final concentration of 3,75O/pL, incubated at 22°C for 20 minutes with 330 nmol/L F'ITC-phalloidin and (to permeabilize the platelets) 0.1% Triton X-100, and then analyzed by flow cytometry.
Glycocalicin Assay
Washed platelets were incubated at 22°C for 20 minutes with 0 to 5 pg/mL cathepsin G. After addition of the proteolytic inhibitor aprotinin (final concentration, 100 pglmL; Sigma), the samples were centrifuged (2,000g for 10 minutes) and the supernatants were stored at -80°C. Supernatant glycocalicin fragment was determined by a competitive inhibition assay using MoAb 6D1, as previously de~cribed.~'
Ristocetin-Induced Platelet Agglutination
Platelets (250,OOO/pL) suspended in autologous plasma were stirred with I .2 mg/mL ristocetin (BioData) in a Lumi-Aggregation Module Series 10008 (Payton, Buffalo, NY). Platelet agglutination was detected by change in light transmission, as previously described.'"
Patient With Bernard-Soulier Syndrome
The patient (N.S.) is a previously unreported 5-year-old boy with Bernard-Soulier syndrome, as determined by a bleeding diathesis characterized by petechiae; platelet counts of 60 to 70 X 109/L; giant platelets on blood smear; bleeding time greater than 20 minutes; normal platelet aggregation in response to epinephrine, adenosine diphosphate, and collagen, but complete lack of ristocetin-induced platelet agglutination; and markedly reduced total platelet GPIb as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Platelet surface glycoproteins of N.S. as a percentage of normal control platelets (determined by flow cytometry with the MoAbs indicated in parentheses) were as follows: GPIb 0% (6D1), 0% (WM23), 0.1% (AK2), 0.3% (AK3), and 0.6% (TM60); GPM 6% (FMC25); GPIb-IX complex 8% (AKl); GPIa-IIa 229% (6F1); GPIIb-IIIa 212% (Y2/51) and 183% (7E3); GPIV 302% (OKM5) and 322% (F13).
Statistical Analysis
Experimental results were expressed as the mean t standard error of the mean (SEM). Statistical analyses were performed by analysis of variance and Student's t-test using Systat (Systat Inc, Evanston, IL) version 5.02 or Epistat (Tracy L. Gustafson, Round Rock, TX).
RESULTS
Cathepsin G Decreases the Platelet Surface Expression of the vWF Binding Site on GPIba
Cathepsin G (10 pg/mLj resulted in a rapid time-dependent decrease in the platelet surface expression of GPIb, as determined by flow cytometry with an MoAb (6D1) directed against the vWF binding site on GPIba (Fig 1) . Cathepsin G (10 pg/mL) also resulted in a rapid time-dependent decrease in ristocetin-induced binding of v W F to platelets, which reflects binding of v W F to GPIbaS6 (Fig 1) . Three minutes after the addition of cathepsin G to a suspension of washed platelets, the platelet surface expression of GPIb was 20.6% 2 1.6% (mean 2 SEM, n = 3) of baseline and the ristocetin-induced binding of v W F to platelets was 0.0% 5 0.0% of baseline. Ten minutes after the addition of cathepsin G, the platelet surface expression of GPIb was 1.7% 2 0.2% of baseline and the ristocetin-induced binding of v W F to platelets remained at 0.0% 2 0.0% of baseline (Fig 1) . The cathepsin-induced decrease in the platelet surface expression of the v W F binding site on GPIba was also demonstrated by the inhibition of ristocetin-induced platelet agglutination (data not shown).
Cathepsin G-Induced Decreases in the Platelet Surface Expression of GPIX and the GPIb-IX Complex Were Similar But Less Than the Cathepsin G-Induced Decrease in the Platelet Surface Expression of GPIb
The effect of cathepsin G on the platelet surface expression of different components of the GPIb-IX complex was assessed. Twenty minutes after the addition of 10 pglmL cathepsin G to a suspension of washed platelets, platelet 
GPlb
QPlX surface antigen expression compared with baseline was 3.6% t 0.1% (n = 5) for GPIb (as determined by MoAb 6D1), 24.0% ? 2.3% for GPIX (as determined by MoAb FMC25), and 23.2% 2 1.5% for the GPIb-IX complex (as determined by MoAb AK1). This quantitative difference between the cathepsin G-induced decrease in different components of the GPIb-IX complex is illustrated in Fig 2. In contrast, when thrombin was substituted for cathepsin G, there was a parallel decrease in the platelet surface expression of the different components of the GPIb-IX complex. Thus, 20 minutes after the addition of l U/mL thrombin to a suspension of washed platelets, platelet surface antigen expression compared with baseline was 23.7% +. 1.5% (n = 5) for GPIb (as determined by 6D1), 24.3% 2 1.6% for GPIX (as determined by FMC25), and 23.8% 1.2% for the GPIb-IX complex (as determined by AK1).
As shown by the single peaks in Fig 2, the cathepsin Ginduced decrease in the platelet surface expression of the GPIb-IX complex was not restricted to a distinct subpopulation of platelets.
COMPLEX
E#ect of Cathepsin G on the Total Platelet Content of
GPIb-IX
We next compared the effects of cathepsin G and thrombin on the total platelet content of GPIb-IX and platelet surface GPIb-IX, as determined by flow cytometric analysis of permeabilized and nonpermeabilized platelets (Fig 3) . Both cathepsin G and thrombin resulted in marked decreases in the platelet surface expression of GPIb, GPIX, and the GPIb-IX complex (Fig 3A, C, and E) . As noted above, cathepsin G, but not thrombin, resulted in a greater decrease in the platelet surface expression of GPIb than GPIX and the GPIb-IX complex (compare Fig 3A with Fig 3C and E) . Furthermore, 10 pg/rnL cathepsin G resulted in a greater decrease in the platelet surface expression of GPIb than did a maximal concentration of thrombin (1 U/mL; Fig 3A) .
In parallel with the cathepsin G-induced decrease in the platelet surface expression of GPIb (Fig 3A) , there was a cathepsin G-induced marked decrease in the total platelet content of GPIb (Fig 3B) . In contrast, despite the cathepsin G-induced decrease in the platelet surface expression of
NON-PERMEABILIZED PERMEABILIZED
I m i
... T GPIX (Fig 3C) and the GPIb-IX complex (Fig 3E) , cathepsin G did not result in any significant change in the total platelet content of GPIX (Fig 3D) or the GPIb-IX complex (Fig 3F) .
Despite the thrombin-induced decrease in the platelet surface expression of GPIb, GPIX, and the GPIb-IX complex ( Fig  3A, C , and E), thrombin did not result in any change in the total platelet content of GPIb, GPIX, or the GPIb-IX complex (Fig 3B, D, and F) . These experiments suggest that, unlike thrombin, cathepsin G resulted in proteolysis of GPIb.
These experiments also demonstrate that, in addition to the previously described non-surface-accessible pool of GPIb (see Michelson Fig 3D with the baseline of Fig 3C) . The GPIb and GPIX in this pool are fully complexed, as determined by MoAb AK1 (compare the baseline of Fig 3F with the baseline of  Fig 3E) .
3A), platelets have a non-surface-accessible pool of GPIX, as determined by MoAb FMC25 (compare the baseline of
Cathepsin G Results in Release of a Glycocalicin
Fragment From Platelets
To confirm that cathepsin G resulted in proteolysis of GPIb from platelets, the supernatant concentration of glycocalicin, a proteolytic product of the G P I~c~?~ was determined. Incubation of washed platelets at 22°C for 20 minutes with cathepsin G resulted in a concentration-dependent increase in the glycocalicin content of the supernatant (Fig 4) . The maximal observed increase in supernatant glycocalicin of 27 nmoyL more than accounted for the calculated total available platelet surface GPIb pool of 3.7 nmol/L (based on a final concentration of 75,000 platelet/pL and assuming 30,000 copies of GPIb on the platelet surfaces6). These data are consistent with the presence of the previously reported non-surface-accessible pool of and with the cathepsin G-induced marked decrease in this pool (Fig 3B) .
Role of Actin Polymerization in the Cathepsin G-Induced Decrease in the Platelet Sur$ace Expression of the GPIb-
IX Complex
To examine the effect of cathepsin G (0.1 to 5 pg/mL) on platelet actin polymerization, experiments were performed with FITC-conjugated phalloidin, which specifically stains polymerized (F) actin." These experiments showed that cathepsin G resulted in a concentration-dependent increase in the F-actin content of washed platelets (data not shown).
To examine the role of actin polymerization in the cathepsin G-induced decrease in the platelet surface expression of the GPIb-IX complex, and in the previously reported cathepsin G-induced increase in the platelet surface expression of P-selectin,6 experiments were performed with 6 pmol/L cytochalasin B, an inhibitor of actin polymerization.'4 Cytochalasin B had no effect on the cathepsin G-induced increase 163 in the platelet surface expression of P-selectin (as determined by MoAb S12; Fig SA) . As expected from our findings of a cathepsin G-induced proteolysis of GPIba (see above), the decrease in the platelet surface expression of GPIba induced by 10 pg/rnL cathepsin G was not inhibited by cytochalasin B (as determined by MoAb 6D1; Fig 5B) . However, the decrease in the platelet surface expression of GPIb induced by 2 to 6 pg/rnL cathepsin G was partially inhibited by cytochalasin B (Fig 5B) , suggesting that at submaximal concentrations of cathepsin G the decreased platelet surface expression of GPIba was via both proteolytic and cytoskeletalmediated mechanisms.
In contrast, the decrease in the platelet surface expression of GPIX (as determined by MoAb FMC25) and of the remnant of the GPIb-IX complex (as determined by MoAb AK1) induced by all tested concentrations of cathepsin G (2 to 10 pg/mL) was completely inhibited by cytochalasin B (Fig 5C  and D) , suggesting a mechanism involving actin polymerization rather than proteolysis. In the presence of cathepsin G, cytochalasin B actually resulted in an increase in the platelet surface expression of the GPIb-IX complex (Fig 5D) , presumably on the basis of increased steric access of AKl to its binding site as a result of GPIba proteolysis.
In contrast to these experiments with cathepsin G, cytochalasin B completely inhibited the thrombin-induced decrease in the platelet surface expression of GPIb, GPIX, and the GPIb-IX complex (data not shown), as previously reported."
Effect of PGI, on the Cathepsin G-Induced Decrease in the Platelet Surface Expression of the GPlb-IX Complex
To further examine the role of platelet activation in the cathepsin G-induced decrease in the platelet surface expression of the GPIb-IX complex, experiments were performed with PG12, an inhibitor of platelet activation. PG12 had no effect on the cathepsin G-induced decrease in the platelet surface expression of GPIb, as determined by MoAb 6D1 (Fig 6) . In contrast, PGIl completely inhibited the cathepsin G-induced decrease in the platelet surface expression of the GPIb-IX complex, as determined by MoAb AK1 (Fig 6) .
Effect of Cathepsin G on the Surface Expression of the GPIb-IX Complex on Fixed Platelets
Metabolic inactivation of platelets by fixation with 1% formaldehyde did not inhibit the cathepsin G-induced decrease in the platelet surface expression of GPIb, as determined by MoAb 6D1 (Fig 7) . However, cathepsin G resulted in minimal decreases in the binding to fixed platelets of MoAbs Th460 (directed against the thrombin binding site on GPIba) and W 2 3 (directed against the macroglycopeptide portion of GPIba). Fixation abolished the cathepsin G-induced decrease in platelet surface GPIX and the GPIb-IX complex, as determined by MoAbs FMC25 and AKI, respectively (Fig 7) . These data show that a metabolically active platelet is required for the cathepsin G-induced decrease in platelet surface GPIX and the GPIb-IX complex, but not for the cathepsin G-induced decrease (proteolysis) in platelet surface GPIb. Furthermore, these data suggest that the cathepsin G-induced proteolysis of GPIba includes the 6D1 epitope but not the TM60 or WM23 epitopes.
Platelet Surface GPIb Is Not Required for the Cathepsin G-Induced Modulation of the Platelet Surface Expression of Either P-selectin or the Remainder of the GPIb-IX Complex
To address the question as to whether cathepsin G-induced proteolysis of GPIb is required for the cathepsin G-induced cytoskeletal-mediated redistribution of the remainder of the GPIb-IX complex or cathepsin G-induced degranulation, two sets of experiments were performed. First, washed platelets were incubated (22°C for 30 minutes) with Serratia marcescens metalloprotease at 2.5 pg/mL. As determined by flow cytometry with MoAb 6D1, the platelet surface GPIb content of Serratia protease-treated platelets was 0.1% t 0.1% (mean 2 SEM, n = 6) of control (non-Serratia proteasetreated) platelets. Serratia protease treatment of platelets had no effect on cathepsin G-induced degranulation, as determined by the platelet surface expression of P-selectin ( Fig  8A) . Serratia protease treatment of platelets resulted in increased platelet binding of the GPIb-IX complex-dependent MoAb AK1 (Fig 8B) , presumably because of increased steric access of AK1 to its binding site as a result of GPIba proteolysis. However, Serratia protease treatment of platelets had no effect on the cathepsin G-induced decrease in the platelet surface expression of the remnant of the GPIb-IX complex (Fig 8B) .
Second, experiments were performed with the platelets of a patient with Bernard-Soulier syndrome, an inherited deficiency of the GPIb-IX complex.s6 The cathepsin G-induced increase in the platelet surface expression of P-selectin was the same for Bernard-Soulier platelets as for normal control platelets (data not shown).
DISCUSSION
In this study, we have shown that neutrophil cathepsin G decreases the platelet surface expression of the GPIb-IX complex, as determined by 3 independent methods: immunologic (flow cytometry with GPIb-IX-specific MoAbs), ligand binding (exogenous vWF in the presence of ristocetin), and functional (ristocetin-induced platelet agglutination). Unlike thrombin,'6.'8-20~2s cathepsin G resulted in proteolysis of the vWF binding site on the a chain of platelet GPIb (defined by MoAb 6D134,35), as determined by increased supernatant glycocalicin fragment (a proteolytic product of GPIbd6); decreased total platelet content of GPIb; and lack similarly found that cathepsin G resulted in proteolysis of GPIba. In the present study, in contrast to the findings with MoAb 6D1, cathepsin G resulted in minimal decreases in the binding to fixed platelets of MoAbs TM60 (directed against the thrombin binding site on GPI~CI~'"~) and WM23 (directed against the macroglycopeptide portion of G P~Y~~*~) . These data suggest that the cathepsin G-induced proteolysis of GPIba includes the 6D1 epitope but not the TM60 or WM23 epitopes.
Furthermore, we now show that, in addition to its proteolytic effect on GPIba (present study and Molino et a121), cathepsin G results in a decrease in the platelet surface expression of GPIX and the remnant of the GPIb-IX complex (defined by MoAbs M C 2 5 and AK1) via a cytoskeletalmediated redistribution rather than via proteolysis, as determined by lack of change in the total platelet content of GPIX and the GPIb-IX complex, and complete inhibition by cytochalasin B, PG12, and prior fixation of platelets.
Cathepsin G binds to platelets via an as yet unidentified specific re~eptor.~' In this study, we used two models of GPIb-deficient platelets (Serratia protease-treated platelets and platelets from a patient with Bernard-Soulier syndrome) to examine whether platelet surface GPIb is required for the cathepsin G-induced modulation of the platelet surface expression of either P-selectin or the remainder of the GPIb-IX complex. Serratia protease results in virtually complete, selective proteolysis of the glycocalicin portion of platelet surface GPIba (this study, Cooper et alZ7 and Yamamoto et alZ8), without any effect on platelet surface GPIX, the remainder of the GPIb-IX complex, or any other surface GP,Z8 and without causing platelet activation." The platelets of our patient with Bernard-Soulier syndrome, an inherited deficiency of GPIb-IX,56 have a greater than 99% reduction in platelet surface GPIb and a 94% reduction in platelet surface GPIX. The results of the experiments with these two models of GPIb-deficient platelets showed that neither platelet surface GPIb nor cathepsin G-induced proteolysis of GPIb are required for the cathepsin G-induced cytoskeletal-mediated redistribution of the remainder of the GPIb-IX complex or for cathepsin G-induced degranulation. Thus, cathepsin G activates platelets and redistributes the remnant GPIb-IX complex via a GPIba-independent pathway. In contrast, the thrombin-induced cytoskeletal-mediated redistribution of the GPIb-IX complex and thrombin-induced degranulation proceed via both GPIba-dependent and GPIba-independent pathways.28359 The fact that cathepsin G-induced proteolysis of GPIb is not required for cathepsin G-induced platelet activation (this study) is comparable to the fact that thrombin-induced proteolysis of GPV is not required for thrombininduced platelet activation. 60 There are many interactions between neutrophils and For example, P-selectin, a component of the platelet a granule membrane that is only expressed on the platelet surface membrane after degranulati~n,'~~~' mediates adhesion of activated platelets to neutrophils and monoc y t e~.~~.~' The precursor of neutrophil-activating peptide-2, a cytokine that causes neutrophil degranulation and chemotaxis, is released by activated platelets.66 Another example is platelet activation by cathepsin G, a serine protease released by the azurophilic granules of stimulated neutrophils."6 It has recently been reported that cathepsin G increases the platelet surface expression of P-selectin' and increases the exposure of the fibrinogen binding site on the platelet surface GPIIb-IIIa complex!."
Although thrombospondin 1 antiserine proteases,z3 and plasma6 are all inhibitors of cathepsin G, the effects of cathepsin G on platelets can occur during close contact between neutrophils and platelets in a protective microenvironment (eg, thrombosis and local inflammati~n).'~.~~ The present finding that neutrophil cathepsin G decreases the platelet surface expression of the GPIb-D( complex, together with the previous finding that neutrophil elastase decreases the platelet surface expression of GPIb,"~" suggests that, in a protective microenvironment, neutrophils play a role in transforming platelets from a state favoring adhesion to damaged vessel walls (mediated by vWF binding to the GPIba component of the GPIb-IX complexs6) to a state favoring platelet-to-platelet aggregation (mediated by the binding of fibrinogen and other ligands to the GPIIb-IIIa complex67) and platelet-to-leukocyte adhesion (mediated by P-~electin~~.'~).
In summary, neutrophil cathepsin G modulates the platelet surface expression of the GPIb-IX complex both by proteolysis of the vWF binding site on GPIba and by a cytoskeletalmediated redistribution of the remainder of the complex. Neither platelet surface GPIb nor cathepsin G-induced proteolysis of GPIba is required for the cathepsin G-induced cytoskeletal-mediated redistribution of the remainder of the platelet surface GPIb-IX complex or for cathepsin G-induced platelet degranulation.
